Organon: ‘Those $4bn-$5bn Biologics – That’s A Nice Place To Play In Biosimilars’

No Plans To Manufacture, Allocating Capital For Partnerships, Company Tells Generics Bulletin

 
• By Dean Rudge
  
Business niche market and specializing in a smaller opportunity as an individual dart going a different way as a metaphor for strategic planning as a 3D illustration.
• Source: Shutterstock

More from Biosimilars

More from Products